Literature DB >> 20152717

C-kit-targeted imaging of gastrointestinal stromal tumor using radiolabeled anti-c-kit monoclonal antibody in a mouse tumor model.

Chizuru Sogawa1, Atsushi B Tsuji, Hitomi Sudo, Aya Sugyo, Chisato Yoshida, Kenichi Odaka, Tomoya Uehara, Yasushi Arano, Mitsuru Koizumi, Tsuneo Saga.   

Abstract

INTRODUCTION: Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor arising from the gastrointestinal tract and highly expresses mutated c-kit. We aimed to develop a specific and sensitive method for detecting GISTs using radiolabeled anti-c-kit monoclonal antibody.
METHODS: A mutated c-kit-expressing cell clone was established by transfecting an expressing vector of mutated c-kit gene into HEK293 human embryonic kidney cells. The tumors were developed by inoculating c-kit-expressing cells into nude mice. (125)I- and (111)In-labeled anti-c-kit antibodies (12A8 and 41A11) were evaluated in vitro by cell binding, competitive inhibition and cellular internalization assays, and in vivo by biodistribution and imaging studies in tumor-bearing mice.
RESULTS: Both (125)I- and (111)In-labeled antibodies showed specific binding with c-kit-expressing cells with high affinity (dissociation constants = 2.2-7.1x10(9) M(-1)). Internalization assay showed that (125)I-labeled antibodies were rapidly internalized and dehalogenated, with the release of (125)I from the cells, resulting in reduction of cell-associated radioactivity with time. In contrast, (111)In-labeled antibody was internalized but did not result in the reduced radioactivity associated with tumor cells. Reflecting this phenomenon, the in vivo tumor uptake of (125)I-labeled antibody was low on Day 1, further decreasing with time, while tumor uptake of (111)In-labeled antibody was high on Day 1, further increasing with time. The xenografted tumor was clearly visualized by scintigraphy after injection of (111)In-labeled antibody.
CONCLUSION: The anti-c-kit monoclonal antibody labeled with a metal radionuclide would be promising for c-kit-targeted imaging of GISTs. (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20152717     DOI: 10.1016/j.nucmedbio.2009.10.008

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  15 in total

1.  Anti-KIT DNA Aptamer for Targeted Labeling of Gastrointestinal Stromal Tumor.

Authors:  Jason K Sicklick; Partha Ray; Sudeep Banerjee; Hyunho Yoon; Mayra Yebra; Chih-Min Tang; Mara Gilardi; Jayanth S Shankara Narayanan; Rebekah R White
Journal:  Mol Cancer Ther       Date:  2020-03-03       Impact factor: 6.261

2.  [Importance of PET for surgery of gastrointestinal stromal tumors].

Authors:  U Ronellenfitsch; B Wängler; S Niedermoser; A Dimitrakopoulou-Strauss; P Hohenberger
Journal:  Chirurg       Date:  2014-06       Impact factor: 0.955

Review 3.  State of the Art in the Treatment of Gastrointestinal Stromal Tumors.

Authors:  Benjami Garlipp; Christiane J Bruns
Journal:  Gastrointest Tumors       Date:  2015-04-21

4.  (18)FDG-PET at 1-Month Intervals Is a Better Predictive Marker for GISTs That Are Difficult to Be Diagnosed Histopathologically: A Case Report.

Authors:  Kazunori Otsuka; Masahiro Takahashi; Hiroshi Nanjo; Hideaki Miyazawa; Masatake Iida; Yuki Abe; Mario Jin; Hirohide Onishi; Manabu Hashimoto; Yuzo Yamamoto; Hiroyuki Shibata
Journal:  Case Rep Oncol Med       Date:  2011-10-11

5.  Evaluation of Efficacy of Radioimmunotherapy with 90Y-Labeled Fully Human Anti-Transferrin Receptor Monoclonal Antibody in Pancreatic Cancer Mouse Models.

Authors:  Aya Sugyo; Atsushi B Tsuji; Hitomi Sudo; Maki Okada; Mitsuru Koizumi; Hirokazu Satoh; Gene Kurosawa; Yoshikazu Kurosawa; Tsuneo Saga
Journal:  PLoS One       Date:  2015-04-20       Impact factor: 3.240

6.  Radioimmunotherapy of pancreatic cancer xenografts in nude mice using 90Y-labeled anti-α6β4 integrin antibody.

Authors:  Winn Aung; Atsushi B Tsuji; Hitomi Sudo; Aya Sugyo; Yoshinori Ukai; Katsushi Kouda; Yoshikazu Kurosawa; Takako Furukawa; Tsuneo Saga
Journal:  Oncotarget       Date:  2016-06-21

7.  Combined treatment of pancreatic cancer xenograft with 90Y-ITGA6B4-mediated radioimmunotherapy and PI3K/mTOR inhibitor.

Authors:  Winn Aung; Atsushi B Tsuji; Hitomi Sudo; Aya Sugyo; Yoshinori Ukai; Katsushi Kouda; Yoshikazu Kurosawa; Takako Furukawa; Tsuneo Saga; Tatsuya Higashi
Journal:  World J Gastroenterol       Date:  2017-11-14       Impact factor: 5.742

8.  Therapeutic efficacy of c-kit-targeted radioimmunotherapy using 90Y-labeled anti-c-kit antibodies in a mouse model of small cell lung cancer.

Authors:  Chisato Yoshida; Atsushi B Tsuji; Hitomi Sudo; Aya Sugyo; Tatsuya Kikuchi; Mitsuru Koizumi; Yasushi Arano; Tsuneo Saga
Journal:  PLoS One       Date:  2013-03-14       Impact factor: 3.240

9.  Evaluation of (89)Zr-labeled human anti-CD147 monoclonal antibody as a positron emission tomography probe in a mouse model of pancreatic cancer.

Authors:  Aya Sugyo; Atsushi B Tsuji; Hitomi Sudo; Kotaro Nagatsu; Mitsuru Koizumi; Yoshinori Ukai; Gene Kurosawa; Ming-Rong Zhang; Yoshikazu Kurosawa; Tsuneo Saga
Journal:  PLoS One       Date:  2013-04-05       Impact factor: 3.240

Review 10.  The C-kit receptor-mediated signal transduction and tumor-related diseases.

Authors:  Jing Liang; Yan-Ling Wu; Bing-Jia Chen; Wen Zhang; Yoshimasa Tanaka; Hiroshi Sugiyama
Journal:  Int J Biol Sci       Date:  2013-05-08       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.